Search Results
10
Everything
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
February 26, 2025 07:00 ET
|
MoonLake Immunotherapeutics AG
Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic...
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 07, 2024 07:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable...